GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Short-Term Debt

GALDY (Galderma Group AG) Short-Term Debt : $6 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Short-Term Debt?

Galderma Group AG's Short-Term Debt for the quarter that ended in Dec. 2024 was $6 Mil.

Galderma Group AG's quarterly Short-Term Debt declined from Dec. 2023 ($39 Mil) to Jun. 2024 ($6 Mil) but then stayed the same from Jun. 2024 ($6 Mil) to Dec. 2024 ($6 Mil).

Galderma Group AG's annual Short-Term Debt increased from . 20 ($0 Mil) to Dec. 2023 ($39 Mil) but then declined from Dec. 2023 ($39 Mil) to Dec. 2024 ($6 Mil).

Galderma Group AG Short-Term Debt Historical Data

The historical data trend for Galderma Group AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Short-Term Debt Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Short-Term Debt
39.00 6.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Short-Term Debt - 39.00 6.00 6.00

Galderma Group AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Galderma Group AG Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Short-Term Debt
Comparable Companies
XSWX:SDZ XSWX:PPGN XSWX:SFZN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124
Traded in Other Exchanges
GDERF:USA GALDz:UK PY30:Germany GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.